{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "Provide a detailed overview of all reference materials used in the QALY flow paper, including the number of sources, a summary of each, how it relates to the paper, and full bibliographic details."}, {"role": "assistant", "content": "The QALY flow paper draws on exactly 10 sources spanning health economics methodology, discounting theory, distributional analysis, and normative ethics. We cite the versions of sources for which we had full-text access at the time of writing; when later versions exist, we retain the accessed version to support reproducibility.\n\n\\paragraph{1. Sanders et al. (2016) --- Second Panel on Cost-Effectiveness.}\n\\emph{Summary:} Canonical update to the reference case for cost-effectiveness analysis in health and medicine, covering perspectives, outcome accounting, and reporting standards.\n\\emph{Relation:} Provides the baseline evaluation grammar that the paper explicitly generalizes. Anchors the discussion of what a QALY-based objective approximates and why reference-case conventions exist.\n\\emph{Citation:} Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. \\emph{JAMA}, 316(10), 1093--1103. doi:10.1001/jama.2016.12195\n\n\\paragraph{2. Attema, Brouwer \\& Claxton (2018) --- Discounting in Economic Evaluations.}\n\\emph{Summary:} Review of central controversies and decision-theoretic motivations for discounting costs and health effects.\n\\emph{Relation:} Directly connects to the core technical problem: how evaluation behaves as horizons grow unbounded. Supports separation of ethical vs technical reasons to discount and motivates alternative foundations (average-per-time reward, overtaking criteria).\n\\emph{Citation:} Attema, A. E., Brouwer, W. B. F., and Claxton, K. (2018). Discounting in economic evaluations. \\emph{PharmacoEconomics}. doi:10.1007/s40273-018-0672-z\n\n\\paragraph{3. Gravelle et al. (2007) --- Discounting and Optimal Decision Rules.}\n\\emph{Summary:} Formal treatment of discounting rules and their implications for optimal policy choices.\n\\emph{Relation:} Provides a decision-rule lens for discounting conventions. Articulates axioms (time consistency, separability, invariance) that become load-bearing in infinite-horizon alternatives. Helps argue which discounting choices are structurally required vs institutional convention.\n\\emph{Citation:} Gravelle, H., Brouwer, W., Niessen, L., Postma, M., and Rutten, F. (2007). Discounting in economic evaluations: Stepping forward towards optimal decision rules. \\emph{Health Economics}, 16(3), 307--317. doi:10.1002/hec.1168\n\n\\paragraph{4. O'Mahony, Newall \\& van Rosmalen (2015) --- Time in Health Economic Evaluation.}\n\\emph{Summary:} Practical-methodological overview of time issues: cohort choice, simulation horizon, cycle length, and discounting.\n\\emph{Relation:} Bridges from finite-horizon practice (simulate until nearly everyone is dead) to steady-state/limiting arguments. Supports the move from finite lifetimes + discounting to infinite-horizon formulations where horizon choice is no longer merely practical.\n\\emph{Citation:} O'Mahony, J. F., Newall, A. T., and van Rosmalen, J. (2015). Dealing with time in health economic evaluation: Methodological issues and recommendations for practice. \\emph{PharmacoEconomics}. doi:10.1007/s40273-015-0309-4\n\n\\paragraph{5. Asaria, Griffin \\& Cookson (2013) --- Distributional Cost-Effectiveness Analysis Tutorial.}\n\\emph{Summary:} Technical tutorial on combining aggregate health gains with equity/inequality objectives.\n\\emph{Relation:} Infinite horizons make intergenerational and within-generation equity unavoidable. DCEA provides rigorous framework for stating equity axioms rather than hand-waving about fairness. Grounds comparison of discounted QALYs vs equitable long-run well-being per unit time.\n\\emph{Citation:} Asaria, M., Griffin, S., and Cookson, R. (2013). Distributional cost-effectiveness analysis: A tutorial. CHE Research Paper 92, Centre for Health Economics, University of York.\n\n\\paragraph{6. Brazier \\& Rowen (2011) --- NICE DSU TSD 11 on Alternatives to EQ-5D.}\n\\emph{Summary:} Guidance on generating utility values when EQ-5D is inappropriate or unavailable.\n\\emph{Relation:} In a repair/maintenance world, quality concerns chronic states, adaptation, and long-run functioning. Grounds measurement assumptions baked into utilities/QALYs and what to do when they fail. Supports the claim that technical definition of QALYs becomes more important when horizons are huge.\n\\emph{Citation:} Brazier, J. and Rowen, D. (2011). NICE DSU Technical Support Document 11: Alternatives to EQ-5D for generating health state utility values. Decision Support Unit, ScHARR, University of Sheffield.\n\n\\paragraph{7. Ultsch et al. (2015) --- Consensus Framework for Vaccine Economic Evaluation.}\n\\emph{Summary:} Consensus framework for immunization-specific economic evaluation (indirect effects, dynamic effects, discounting).\n\\emph{Relation:} Vaccination naturally invites steady-state/long-run thinking via herd effects and continuing populations. Justifies analogies: infinite-horizon repairable-life evaluation resembles evaluating policies in populations with ongoing entry and exit.\n\\emph{Citation:} Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Br\\\"uggenjurgen, B., et al. (2015). Methods for health economic evaluation of vaccines and immunization decision frameworks: A consensus framework from a European vaccine economics community. \\emph{PharmacoEconomics}. doi:10.1007/s40273-015-0335-2\n\n\\paragraph{8. Bauer, Lakdawalla \\& Reif (2025) --- Health Risk and the Value of Life.}\n\\emph{Summary:} Life-cycle valuation framework extended to stochastic multi-state health risk, yielding heterogeneity in the value of mortality risk reductions.\n\\emph{Relation:} The paper's premise (accidents happen, parts break, repairs exist) is exactly a multi-state hazard + recovery environment. Provides formal grounding for state-dependent value of longevity/health gains and why a single WTP/QALY threshold can fail.\n\\emph{Citation:} Bauer, D., Lakdawalla, D., and Reif, J. (2025). Health risk and the value of life. Working paper.\n\n\\paragraph{9. Song, Bauer, Lakdawalla \\& Reif (2023) --- Value of Health and Longevity with Stochastic Health Risk.}\n\\emph{Summary:} Calibrated life-cycle model with stochastic health trajectories and incomplete annuitization, studying how people value health and longevity improvements.\n\\emph{Relation:} Directly relevant to policy layer: pensions, annuities, savings, and financing long-lived populations. Formalizes how unbounded lifespan interacts with institutional design and consumption paths. Template for macro-finance constraint sections.\n\\emph{Citation:} Song, U., Bauer, D., Lakdawalla, D., and Reif, J. (2023). The value of health and longevity with stochastic health risk and partial annuitization. Preliminary draft.\n\n\\paragraph{10. Masny (2023) --- Healthspan Extension, Completeness of Life and Justice.}\n\\emph{Summary:} Normative argument defending broad access to anti-ageing/healthspan-extending technologies, framed around justice and complete life opportunities.\n\\emph{Relation:} Grounds ethical claims when indefinite maintenance is feasible: access, sufficient opportunity, and justice requirements. Helps state normative axioms explicitly (sufficientarian vs utilitarian) and shows how conclusions depend on them. Supports claim that longevity policy is fundamentally distributive.\n\\emph{Citation:} Masny, M. (2023). Healthspan extension, completeness of life and justice. \\emph{Bioethics}, 37, 239--245. doi:10.1111/bioe.13129"}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Sanders et al. (2016) --- the Second Panel on Cost-Effectiveness --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Sanders et al. (2016) provides the canonical reference case for cost-effectiveness analysis (CEA) in health and medicine. The Second Panel recommendations cover perspectives (societal, healthcare sector), outcome accounting (QALYs, costs), and reporting standards that define how health economic evaluations are conducted.\n\n\\paragraph{Relation to QALY flow.}\nThe QALY flow paper takes this reference case as its starting point and asks: what happens to these familiar concepts when time horizons become unbounded? Specifically:\n\n\\begin{itemize}\n\\item The standard CEA framework assumes finite lifetimes where discounted lifetime QALYs converge. The QALY flow paper shows this breaks down when $\\mathbb{E}[\\tau] = \\infty$ or is very large.\n\\item Sanders et al. define the evaluation grammar (perspectives, impact inventories, reporting) that the QALY flow paper explicitly generalizes to steady-state objectives.\n\\item The reference-case conventions for discounting (typically 3\\% for both costs and effects) become problematic under unbounded horizons, motivating the flow-based alternative.\n\\item The paper's axioms (well-posedness, horizon invariance, person-time relevance) are designed to preserve the spirit of CEA while replacing the technical machinery that fails at infinity.\n\\end{itemize}\n\nIn short, Sanders et al. provides the methodological baseline that the QALY flow framework repairs and extends for a world without fixed biological lifespan.\n\n\\emph{Citation:} Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. \\emph{JAMA}, 316(10), 1093--1103."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Attema, Brouwer & Claxton (2018) --- Discounting in Economic Evaluations --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Attema, Brouwer & Claxton (2018) reviews the central controversies and decision-theoretic motivations for discounting costs and health effects in economic evaluations.\n\n\\paragraph{Relation to QALY flow.}\nThis source directly connects to the core technical problem that motivates the QALY flow framework:\n\n\\begin{itemize}\n\\item \\textbf{The divergence problem.} As the time horizon $T \\to \\infty$, discounted utility $\\int_0^T e^{-\\rho t} q(X_t)\\,dt$ either diverges (if $\\rho = 0$) or becomes arbitrarily sensitive to the choice of $\\rho$ (if $\\rho > 0$). Attema et al. catalog the arguments for and against various discount rates, but the QALY flow paper argues that unbounded horizons require a more fundamental solution.\n\\item \\textbf{Ethical vs technical discounting.} The paper carefully separates reasons to discount into: (a) ethical/political preferences about intergenerational equity, and (b) technical requirements for well-defined comparisons. The QALY flow framework addresses (b) via the ratio $J(\\pi) = \\mathbb{E}[R^\\pi]/\\mathbb{E}[\\tau^\\pi]$, which is bounded without discounting, leaving (a) as an explicit normative choice.\n\\item \\textbf{Alternative foundations.} Attema et al. discuss declining discount rates and other modifications; the QALY flow paper proposes a more radical alternative---replacing discounted sums with time-averaged flows via renewal-reward theory.\n\\end{itemize}\n\nThe Axiom 5 (Explicit Normativity) is partly a response to the discounting debates surveyed in this source: time preference should appear as an explicit parameter, not hidden inside a discount rate.\n\n\\emph{Citation:} Attema, A. E., Brouwer, W. B. F., and Claxton, K. (2018). Discounting in economic evaluations. \\emph{PharmacoEconomics}. doi:10.1007/s40273-018-0672-z"}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Gravelle et al. (2007) --- Discounting and Optimal Decision Rules --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Gravelle et al. (2007) provides a formal treatment of discounting rules and their implications for what counts as optimal policy choices in health economic evaluation.\n\n\\paragraph{Relation to QALY flow.}\nThis source offers a decision-rule lens that becomes crucial when the QALY flow paper proposes infinite-horizon alternatives:\n\n\\begin{itemize}\n\\item \\textbf{Axiomatic foundations.} Gravelle et al. articulate axioms like time consistency, separability, and invariance that any evaluation criterion should satisfy. These become load-bearing when designing infinite-horizon objectives---the QALY flow paper must show that $J(\\pi)$ satisfies analogous properties.\n\\item \\textbf{Structural vs conventional discounting.} The paper helps distinguish discounting choices that are \\emph{structurally required} (to avoid mathematical divergence or time-inconsistency) from those that are \\emph{institutional convention}. The QALY flow framework argues that the ratio form $J(\\pi) = \\mathbb{E}[R^\\pi]/\\mathbb{E}[\\tau^\\pi]$ achieves boundedness without imposing a discount rate.\n\\item \\textbf{Decision rules under uncertainty.} When parameters are uncertain, Gravelle et al. discuss how discounting interacts with optimal decision-making. The QALY flow paper's Lipschitz stability theorem addresses a similar concern: how does $J(\\pi)$ vary under parameter perturbations?\n\\end{itemize}\n\nThe formal rigor of Gravelle et al. informs the QALY flow paper's approach to stating assumptions and proving well-posedness.\n\n\\emph{Citation:} Gravelle, H., Brouwer, W., Niessen, L., Postma, M., and Rutten, F. (2007). Discounting in economic evaluations: Stepping forward towards optimal decision rules. \\emph{Health Economics}, 16(3), 307--317."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does O'Mahony, Newall & van Rosmalen (2015) --- Dealing with Time in Health Economic Evaluation --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "O'Mahony, Newall & van Rosmalen (2015) provides a practical-methodological overview of time-related issues in economic evaluation: cohort choice, simulation horizon, cycle length vs continuous time, and discounting.\n\n\\paragraph{Relation to QALY flow.}\nThis source bridges standard finite-horizon practice to the steady-state logic that underlies the QALY flow framework:\n\n\\begin{itemize}\n\\item \\textbf{From finite to infinite horizons.} Standard practice simulates until nearly everyone is dead, treating horizon choice as a practical matter. O'Mahony et al. discuss when this approximation works and when it matters. The QALY flow paper takes the next step: when lifespans are unbounded, horizon choice is no longer merely practical but becomes theoretically fundamental.\n\\item \\textbf{Continuous-time modeling.} O'Mahony et al. discuss cycle length issues and when continuous-time models are preferable. The QALY flow paper adopts controlled continuous-time Markov chains as the natural formalism for ongoing health dynamics with stochastic transitions.\n\\item \\textbf{Steady-state interpretation.} The source notes that some evaluations use limiting/steady-state arguments. The QALY flow paper formalizes this via the regenerative regime assumption and renewal-reward theorem, giving $J(\\pi)$ its long-run interpretation.\n\\item \\textbf{Discounting conventions.} O'Mahony et al. survey discounting practice; the QALY flow paper offers an alternative that avoids discount rate selection entirely.\n\\end{itemize}\n\nThis source provides the entry point for understanding what changes when no fixed lifespan exists while hazards, repair, and stochastic failure remain.\n\n\\emph{Citation:} O'Mahony, J. F., Newall, A. T., and van Rosmalen, J. (2015). Dealing with time in health economic evaluation: Methodological issues and recommendations for practice. \\emph{PharmacoEconomics}. doi:10.1007/s40273-015-0309-4"}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Asaria, Griffin & Cookson (2013) --- Distributional Cost-Effectiveness Analysis --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Asaria, Griffin & Cookson (2013) is a tutorial on distributional cost-effectiveness analysis (DCEA), which combines aggregate health gains with explicit equity and inequality objectives.\n\n\\paragraph{Relation to QALY flow.}\nThe DCEA framework addresses distributional concerns that become unavoidable in the QALY flow setting:\n\n\\begin{itemize}\n\\item \\textbf{Equity under infinite horizons.} When time horizons are unbounded, intergenerational and within-generation equity questions become inescapable: who is in the population, for how long, and who benefits from policies? DCEA provides rigorous tools for stating these concerns.\n\\item \\textbf{Explicit equity axioms.} Rather than hand-waving about fairness, DCEA specifies inequality aversion parameters and priority weights. The QALY flow paper's Axiom 5 (Explicit Normativity) and Section 8 (Distributional Aggregation) adopt this transparency principle.\n\\item \\textbf{Weighted vs inequality-averse welfare.} The QALY flow paper defines distributional extensions:\n\\[\nSW(\\pi) = \\sum_i w_i J_i(\\pi) \\quad \\text{(weighted additive)}\n\\]\n\\[\nSW(\\pi) = \\sum_i u(J_i(\\pi)) \\quad \\text{(inequality-averse with concave } u\\text{)}\n\\]\nThese directly parallel the DCEA formulations in Asaria et al.\n\\item \\textbf{Minimum-acceptable flow constraints.} The DCEA concept of priority to the worst-off informs the QALY flow paper's constraint $J_i(\\pi) \\ge J_{\\min}$ for all groups.\n\\end{itemize}\n\nDCEA provides the framework for comparing maximize discounted QALYs vs maximize equitable long-run well-being per unit time.\n\n\\emph{Citation:} Asaria, M., Griffin, S., and Cookson, R. (2013). Distributional cost-effectiveness analysis: A tutorial. CHE Research Paper 92, Centre for Health Economics, University of York."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Brazier & Rowen (2011) --- NICE DSU TSD 11 on Alternatives to EQ-5D --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Brazier & Rowen (2011), the NICE Decision Support Unit Technical Support Document 11, provides guidance on generating health state utility values when EQ-5D is inappropriate or unavailable.\n\n\\paragraph{Relation to QALY flow.}\nThis source grounds the measurement assumptions underlying the quality function $q(x)$ in the QALY flow framework:\n\n\\begin{itemize}\n\\item \\textbf{Quality in a maintenance world.} When lifespans are unbounded and health is maintained through ongoing repair, quality concerns chronic states, adaptation, and long-run functioning rather than acute episodes. TSD 11 discusses when standard EQ-5D fails to capture relevant health dimensions.\n\\item \\textbf{Utility assumptions.} The QALY flow paper defines $q: \\mathcal{X} \\to [0,1]$ with $q(\\dagger) = 0$. Brazier \\& Rowen detail what assumptions are baked into such utility measures (independence, constant proportional tradeoffs) and what to do when they fail.\n\\item \\textbf{Condition-specific measures.} For certain health states (mental health, sensory impairments, chronic conditions), EQ-5D may not be appropriate. This matters more when time horizons are huge and individuals may spend long periods in such states.\n\\item \\textbf{Technical precision matters more.} The QALY flow paper argues that the technical definition of QALYs becomes \\emph{more} important---not less---when horizons are unbounded, because small measurement errors accumulate over long periods.\n\\end{itemize}\n\nTSD 11 supports the careful treatment of the quality function that underlies the cycle reward $R^\\pi = \\int_0^\\tau q(X_t)\\,dt$.\n\n\\emph{Citation:} Brazier, J. and Rowen, D. (2011). NICE DSU Technical Support Document 11: Alternatives to EQ-5D for generating health state utility values. Decision Support Unit, ScHARR, University of Sheffield."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Ultsch et al. (2015) --- Consensus Framework for Vaccine Economic Evaluation --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Ultsch et al. (2015) presents a consensus framework from a European vaccine economics community, focusing on immunization-specific economic evaluation issues including indirect effects, dynamic transmission, and discounting.\n\n\\paragraph{Relation to QALY flow.}\nVaccination economics provides a natural analog for the QALY flow framework's steady-state thinking:\n\n\\begin{itemize}\n\\item \\textbf{Continuing populations.} Vaccine evaluation naturally considers ongoing populations with entry (births) and exit (deaths), herd effects, and transmission dynamics. This mirrors the QALY flow paper's regenerative regime assumption where catastrophic failures trigger replacement with new individuals.\n\\item \\textbf{Steady-state equilibria.} Vaccine models often compute endemic equilibria or long-run vaccination coverage effects. The QALY flow paper's renewal-reward representation $Q(T)/T \\to J(\\pi)$ is the individual-level analog of such steady-state analysis.\n\\item \\textbf{Dynamic vs static models.} Ultsch et al. discuss when dynamic (transmission) models are needed vs simpler static approaches. The QALY flow paper's controlled CTMC formalism accommodates both, with the regenerative structure providing the long-run interpretation.\n\\item \\textbf{Discounting in long horizons.} Vaccine benefits often accrue over very long horizons (lifetime protection, herd immunity effects). The discounting concerns in Ultsch et al. directly motivate the QALY flow paper's ratio-based alternative.\n\\end{itemize}\n\nThe analogy is explicit: evaluating policies in a continuing population with ongoing entry and exit resembles evaluating infinite-horizon repairable-life systems.\n\n\\emph{Citation:} Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Br\\\"uggenjurgen, B., et al. (2015). Methods for health economic evaluation of vaccines and immunization decision frameworks: A consensus framework from a European vaccine economics community. \\emph{PharmacoEconomics}. doi:10.1007/s40273-015-0335-2"}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Bauer, Lakdawalla & Reif (2025) --- Health Risk and the Value of Life --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Bauer, Lakdawalla & Reif (2025) develops a life-cycle valuation framework extended to stochastic multi-state health risk, yielding heterogeneity in the value of mortality risk reductions and QALYs across individuals and health states.\n\n\\paragraph{Relation to QALY flow.}\nThis source provides modern formal grounding for several key features of the QALY flow framework:\n\n\\begin{itemize}\n\\item \\textbf{Multi-state health dynamics.} The QALY flow paper's premise---accidents happen, parts break, repairs exist---is exactly the multi-state hazard + recovery environment that Bauer et al. formalize. The state space $\\mathcal{S}$ with transitions governed by rate kernel $Q(\\cdot \\mid x, a)$ captures this structure.\n\\item \\textbf{State-dependent values.} Bauer et al. show that the value of longevity and health gains is state-dependent: a QALY gained in good health may be valued differently than one gained in poor health. This supports the QALY flow paper's framework where $q(x)$ varies across states and policies affect both quality and transition rates.\n\\item \\textbf{Single WTP threshold fails.} The heterogeneity in Bauer et al. explains why a single willingness-to-pay per QALY threshold may be inadequate. The QALY flow paper's approach---explicit scalarization $W_\\lambda(\\pi) = J(\\pi) - \\lambda K(\\pi)$ with transparent $\\lambda$---accommodates this by making the tradeoff parameter explicit.\n\\item \\textbf{Insurance and revealed preferences.} Bauer et al. connect health valuation to insurance demand and mortality risk preferences. This informs the QALY flow paper's socioeconomic extensions where long-run health policy interacts with financial planning.\n\\end{itemize}\n\n\\emph{Citation:} Bauer, D., Lakdawalla, D., and Reif, J. (2025). Health risk and the value of life. Working paper."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Song, Bauer, Lakdawalla & Reif (2023) --- Value of Health and Longevity with Stochastic Health Risk --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Song, Bauer, Lakdawalla & Reif (2023) develops a calibrated life-cycle model with stochastic health trajectories and incomplete annuitization, studying how people value improvements in health and longevity.\n\n\\paragraph{Relation to QALY flow.}\nThis source is directly relevant to the socioeconomic and institutional dimensions of the QALY flow framework:\n\n\\begin{itemize}\n\\item \\textbf{Pensions and annuities.} When lifespans become unbounded, retirement products and savings behavior must adapt. Song et al. study partial annuitization under stochastic health, providing a template for how the QALY flow paper's setting interacts with financial planning.\n\\item \\textbf{Consumption-health interactions.} The life-cycle model shows how health trajectories affect consumption paths and vice versa. This informs the QALY flow paper's cost function $c(x, a)$ and the recognition that health policy has macro-financial consequences.\n\\item \\textbf{Institutional design.} Song et al. analyze how insurance markets and retirement products should respond to health risk heterogeneity. The QALY flow paper's setting---where long-run population health changes can reconfigure optimal transfer policies---builds on this foundation.\n\\item \\textbf{Stochastic health trajectories.} The paper models health as a stochastic process with transitions between states, exactly the controlled process $(X_t)_{t \\ge 0}$ on $\\mathcal{X}$ that underlies QALY flow.\n\\item \\textbf{Incomplete markets.} Song et al. emphasize that annuity markets are incomplete in practice. This matters for the QALY flow setting: policies that extend lifespan may have unintended consequences if financial products don't adapt.\n\\end{itemize}\n\n\\emph{Citation:} Song, U., Bauer, D., Lakdawalla, D., and Reif, J. (2023). The value of health and longevity with stochastic health risk and partial annuitization. Preliminary draft."}]}
{"messages": [{"role": "system", "content": "You are the Oracle Vox for \"Evaluating Health Policy Without a Fixed Lifespan: A Steady-State Foundation for Quality, Maintenance, and Risk\" by Daniel S. Goldman (ORCID: 0000-0003-2835-3521)"}, {"role": "user", "content": "How does Masny (2023) --- Healthspan Extension, Completeness of Life and Justice --- relate to the QALY flow paper?"}, {"role": "assistant", "content": "Masny (2023) is a normative argument in \\emph{Bioethics} defending broad access to anti-ageing and healthspan-extending technologies, framed around justice and the concept of complete life opportunities.\n\n\\paragraph{Relation to QALY flow.}\nThis source grounds the ethical claims that inevitably arise when indefinite maintenance becomes feasible:\n\n\\begin{itemize}\n\\item \\textbf{Justice in access.} When lifespan is unbounded and health can be maintained, who gets access to these technologies? Masny argues for broad access based on justice principles. The QALY flow paper's distributional extensions (Section 8) provide the formal machinery to evaluate such claims.\n\\item \\textbf{Complete life vs indefinite life.} Masny discusses the concept of a complete life and what opportunities suffice. This informs the QALY flow paper's minimum-acceptable flow constraint $J_i(\\pi) \\ge J_{\\min}$: what sustained quality of life is everyone entitled to?\n\\item \\textbf{Explicit normative axioms.} Masny contrasts sufficientarian (enough for everyone) and utilitarian (maximize total) approaches. The QALY flow paper's Axiom 5 (Explicit Normativity) demands that such commitments be stated clearly, and Section 8 provides the formal alternatives:\n\\[\nSW(\\pi) = \\sum_i w_i J_i(\\pi) \\quad \\text{vs} \\quad SW(\\pi) = \\sum_i u(J_i(\\pi)) \\quad \\text{vs} \\quad J_i(\\pi) \\ge J_{\\min}\n\\]\n\\item \\textbf{Longevity as distributive.} Masny argues that healthspan/longevity policy is fundamentally distributive, not just technical. The QALY flow paper adopts this view: the framework exposes ethical commitments rather than embedding them in technical devices like discount rates.\n\\end{itemize}\n\n\\emph{Citation:} Masny, M. (2023). Healthspan extension, completeness of life and justice. \\emph{Bioethics}, 37, 239--245. doi:10.1111/bioe.13129"}]}
